Nuvectis Pharma, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ, 07024
Mailing Address 1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ, 07024
Phone 360-837-7232
Fiscal Year End 1231
EIN 862405608
Financial Overview
FY2025
$31.71M
Total Assets
$18.41M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| S-3 Shelf registration for future offerings | February 13, 2026 | View on SEC |
| 10-K Annual financial report | February 11, 2026 | View on SEC |
| 8-K Current report of material events | February 11, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | November 6, 2025 | View on SEC |
| 4 Insider stock transaction report | November 6, 2025 | View on SEC |
| 4 Insider stock transaction report | November 6, 2025 | View on SEC |
Annual Reports
10-K February 11, 2026
- Clinical-stage pharmaceutical company focused on innovative oncology therapies to address significant unmet medical needs.
- Pipeline features NXP900, an experimental drug candidate currently undergoing early-stage clinical development for various solid tumors.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.